The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL

Flinn, I. W., Hillmen, P., Montillo, M., Nagy, Z., Illes, A., Etienne, G., Delgado, J., Kuss, B. J., Tam, C. S., Gasztonyi, Z., Offner, F., Lunin, S., Bosch, F., Davids, M. S., Lamanna, N., Jaeger, U., Ghia, P., Cymbalista, F., Portell, C. A., Skarbnik, A. P., Cashen, A. F., Weaver, D. T., Kelly, V. M., Turnbull, B., Stilgenbauer, S.
American Society of Hematology (ASH)
Published 2018